These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 20009104)

  • 1. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
    Guo D; Prins RM; Dang J; Kuga D; Iwanami A; Soto H; Lin KY; Huang TT; Akhavan D; Hock MB; Zhu S; Kofman AA; Bensinger SJ; Yong WH; Vinters HV; Horvath S; Watson AD; Kuhn JG; Robins HI; Mehta MP; Wen PY; DeAngelis LM; Prados MD; Mellinghoff IK; Cloughesy TF; Mischel PS
    Sci Signal; 2009 Dec; 2(101):ra82. PubMed ID: 20009104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
    Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
    Guo D; Hildebrandt IJ; Prins RM; Soto H; Mazzotta MM; Dang J; Czernin J; Shyy JY; Watson AD; Phelps M; Radu CG; Cloughesy TF; Mischel PS
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12932-7. PubMed ID: 19625624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
    Hegi ME; Diserens AC; Bady P; Kamoshima Y; Kouwenhoven MC; Delorenzi M; Lambiv WL; Hamou MF; Matter MS; Koch A; Heppner FL; Yonekawa Y; Merlo A; Frei K; Mariani L; Hofer S
    Mol Cancer Ther; 2011 Jun; 10(6):1102-12. PubMed ID: 21471286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
    Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
    Zhu H; Cao X; Ali-Osman F; Keir S; Lo HW
    Cancer Lett; 2010 Aug; 294(1):101-10. PubMed ID: 20153921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
    Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
    J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway.
    Smith TM; Gilliland K; Clawson GA; Thiboutot D
    J Invest Dermatol; 2008 May; 128(5):1286-93. PubMed ID: 17989724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target.
    Zalcman N; Gutreiman M; Shahar T; Weller M; Lavon I
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SREBP-1 activation by glucose mediates TGF-β upregulation in mesangial cells.
    Uttarwar L; Gao B; Ingram AJ; Krepinsky JC
    Am J Physiol Renal Physiol; 2012 Feb; 302(3):F329-41. PubMed ID: 22031849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
    Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
    Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydrotestosterone induces SREBP-1 expression and lipogenesis through the phosphoinositide 3-kinase/Akt pathway in HaCaT cells.
    Zhou BR; Huang QH; Xu Y; Wu D; Yin ZQ; Luo D
    Lipids Health Dis; 2012 Nov; 11():156. PubMed ID: 23153363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
    Yeo AT; Jun HJ; Appleman VA; Zhang P; Varma H; Sarkaria JN; Charest A
    Oncogene; 2021 Apr; 40(15):2682-2696. PubMed ID: 33707748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib and erlotinib inhibits growth of c-Met
    Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
    Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.